Iodine-123 MNI 672

Drug Profile

Iodine-123 MNI 672

Alternative Names: I-23-labelled MNI-672; Iodine-123-labelled MNI-672

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Molecular NeuroImaging
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 16 May 2016 Phase-I development is ongoing in USA
  • 01 Apr 2015 Molecular NeuroImaging completes a phase I trial in Alzheimer's disease (Diagnosis) in USA (IV)
  • 01 Apr 2013 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top